The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cdercder
明亮尔蓝
GingerF
arniu2008
大力的冬萱
v0id
施含莲
十三
LuciusLLLX
丰富语蕊
OK
lx
ale
逐梦白痴
sagitar
南柯
嘉心糖
闫霄溯
yyds
皖公网安备34019202002308
